Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1868 • ACR Convergence 2020
Comparison of Quality of Life Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Anne Boel¹, Miranda van Lunteren², Karen Fagerli³, Sofia Exarchou⁴, Roberta Ramonda⁵, Marleen van de Sande⁶, Désirée van der Heijde⁷ and Floris van Gaalen⁸, ¹Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, ²Leiden University Medical Centre, Weesp, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, Malmo, Sweden, ⁵University of Padova, Padova, Italy, ⁶Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center (LUMC), Leiden, Netherlands
Background/Purpose: The aim of this study was to compare quality of life (QoL) between chronic back pain (CBP) patients with and without a diagnosis of…
Abstract Number: 1893 • ACR Convergence 2020
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Corinne Miceli-Richard¹, Denis Poddubnyy², Atul Deodhar³, Weibin Bao⁴, Craig Parman⁵, Brian Porter⁶ and Effie Pournara⁵, ¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharmaceuticals Corporation, East Hannover, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
Abstract Number: 0084 • ACR Convergence 2020
Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort
Natalia Cabrera¹, Vannia Valinotti², Gabriela Avila-Pedretti¹, Sonia Cabrera², Patricia Melgarejo³, Zoilo Morel⁴, Lourdes Roman², Pedro Babak⁴, Rodrigo Acosta², Romina Glitz⁴, Darwin Cordovilla⁵, Roger Rolon⁴, Magali Zanotti-Cavazzoni¹, Marco Antonio Franco Britos⁶, Marcos Vazquez², Pedro Delgadillo⁴, Isabel Acosta², María del Carmen Martinez⁴, Gabriel Elizaur⁴, María Teresa Romero⁴, Ernesto Paredes⁴, Paloma de Abreu¹ and Leticia Segovia⁷, ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Hospital de Clínicas, Asunción, Paraguay, ³Hospital IPS, Villa Rica, Paraguay, ⁴Hospital Central del Instituto de Previsión Social, Asunción, Paraguay, ⁵Instituto Nacional de Reumatología, Montevideo, Uruguay, ⁶Instituto de Previsi�n Social, Asunci�n, Central, Paraguay, ⁷Hospital del IPS, Asunción, Paraguay
Background/Purpose: The Paraguayan-Uruguayan cohort of patients with rheumatic inflammatory diseases (BIOBADAGUAY), collect clinical and epidemiological information on adults and children patients receiving biological therapies (BT).…
Abstract Number: 0740 • ACR Convergence 2020
Card9 Promotes Th17-mediated Arthritis and Spondylitis via Control of Acute Pathogenic Neutrophil Responses in SKG Mice
Holly Rosenzweig¹, Emily Vance¹, Ellen Lee¹ and Ruth Napier¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR
Background/Purpose: Caspase recruitment domain-containing protein 9 (CARD9) is an intracellular signal transduction molecule that mediates antimicrobial responses following activation of C-type lectin receptors (ie. Dectin-1) by…
Abstract Number: 1312 • ACR Convergence 2020
Time-dependent Analysis of Incident Extra-articular Manifestations and Comorbidities in Axial Spondyloarthritis
Gillian Fitzgerald¹, George Tomlinson², Steve Ramkissoon³, Sophie Wojcik⁴, Robert Inman⁵ and Nigil Haroon⁶, ¹Toronto Western Hospital, Toronto, ON, Canada, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴UHN, Montreal, QC, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) patients have higher morbidity and mortality compared to healthy controls. Much of this excess disease burden is related to extra-articular manifestations…
Abstract Number: 1364 • ACR Convergence 2020
Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
Xenofon Baraliakos¹, Atul Deodhar², Maxime Dougados³, Marga Oortgiesen⁴, Natasha de Peyrecave⁵, Martin Bauer⁶, Thomas Vaux⁵, Carmen Fleurinck⁷ and Désirée van der Heijde⁸, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ²Oregon Health & Science University, Portland, OR, ³Université de Paris, Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Bimekizumab (BKZ), a monoclonal antibody that selectively inhibits interleukin (IL)-17A and IL-17F, has demonstrated clinical efficacy in patients with ankylosing spondylitis (AS) treated over…
Abstract Number: 1869 • ACR Convergence 2020
“Rheum to Diagnosis”: Uncovering Impediments to Accurate Diagnosis of Non-radiographic Axial Spondylarthritis (nr-axSpA)
Sonam Kiwalkar¹, Atul Deodhar¹ and Richard Howard², ¹Oregon Health & Science University, Portland, OR, ²Spondylitis Association of America, Van Nuys, CA
Background/Purpose: In the US, there is up to a 14-year delay in axSpA diagnosis, which is likely greater for nr-axSpA.1 Impediments to timely diagnosis of…
Abstract Number: 1894 • ACR Convergence 2020
Use of Facebook and Electronic Patient Portal to Identify Axial Spondyloarthritis in Patients with Chronic Back Pain
Yuliya Afinogenova¹, Swetha Alexander², Andrew Haims³ and Abhijeet Danve⁴, ¹Yale University, Orange, CT, ²University of Connecticut, New Haven, ³Yale University, New Haven, CT, ⁴Yale University, Rocky Hill, CT
Background/Purpose: Delay in diagnosis of Axial Spondyloarthritis (axSpA) remains a significant unmet need and can be partially attributed to lack of timely rheumatology referral. Current…
Abstract Number: 0154 • ACR Convergence 2020
Treatment Decision Making Among Axial Spondyloarthritis Patients: Real-World Data from the ArthritisPower Registry
William Nowell¹, Theresa Hunter², Kelly Gavigan³, Jeffrey R Curtis⁴, William Malatestinic⁵, Rebecca Bolce⁵, Jeffrey Lisse⁵, Andris Kronbergs⁵, Carol Himelein⁵, Jennifer Walker⁶ and Jessica Walsh⁷, ¹Global Healthy Living Foundation, New York City, NY, ²Eli Lilly and Company, Indianapolis, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Global Health Living Foundation, New York City, NY, ⁷University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapy has been shown to be effective in the treatment of axial spondyloarthritis (axSpA).1,2 Little is understood about axSpA…
Abstract Number: 0876 • ACR Convergence 2020
Gender Differences in Baseline Clinical Characteristics Among Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: Data from 3 Randomized Ixekizumab Controlled Trials
Marina Magrey¹, Kurt de Vlam², Rebecca Bolce³, Soyi Liu-Leage⁴, Danting Zhu⁴, Theresa Hunter³, David Sandoval³ and Irene van der Horst-Bruinsma⁵, ¹Case Western Reserve University School of Medicine, Cleveland, OH, ²Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, ³Eli Lilly and Company, Indianapolis, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to placebo in the treatment of patients with axial spondyloarthritis (axSpA) (Dougados M et…
Abstract Number: 1315 • ACR Convergence 2020
Exploring the Prevalence and Factors Associated with Fatigue in Axial Spondyloarthritis in a Multiethnic Asian Cohort in Singapore
Wei Ze Lim¹, Warren Fong², Yu Heng Kwan³ and Ying Ying Leung², ¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Singapore, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, Singapore, ³Duke-NUS Medical School, Singapore, Singapore, Singapore
Background/Purpose: Fatigue is a cardinal symptom of axial spondyloarthritis (axSpA) that poses management challenges. Data on fatigue amongst Asian patients with axSpA is limited. Ethnicity…
Abstract Number: 1365 • ACR Convergence 2020
Machine Learning-based Berlin Scoring of Magnetic Resonance Images of the Spine in Patients with Ankylosing Spondylitis: Analysis of Data from a Phase 3 Trial with Secukinumab
Amir Jamaludin¹, Rhydian Windsor¹, Sarim Ather¹, Timor Kadir¹, Andrew Zisserman¹, Juergen Braun², Lianne Gensler³, Pedro Machado⁴, Mikkel Østergaard⁵, Denis Poddubnyy⁶, Thibaud Coroller⁷, Brian Porter⁷, Shephard Mpofu⁸ and Aimee Readie⁷, ¹University of Oxford, Oxford, United Kingdom, ²Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany, ³University of California San Francisco, San Francisco, CA, ⁴University College London, London, United Kingdom, ⁵Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Magnetic resonance imaging (MRI) offers a non-invasive and objective method of early diagnosis and classification, monitoring disease burden and treatment response for patients (pts)…
Abstract Number: 1871 • ACR Convergence 2020
Comparison of Work Productivity Outcomes Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthritis Caught Early Cohort
Anne Boel¹, Miranda van Lunteren², Karen Fagerli³, Roberta Ramonda⁴, Sofia Exarchou⁵, Marleen van de Sande⁶, Floris van Gaalen⁷ and Désirée van der Heijde⁸, ¹Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, ²Leiden University Medical Centre, Weesp, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University of Padova, Padova, Italy, ⁵Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, Malmo, Sweden, ⁶Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The aim of this study was to compare work-productivity and activity impairment outcomes after two-year follow-up between chronic back pain (CBP) patients with and…
Abstract Number: 1897 • ACR Convergence 2020
Trends in Hospitalizations for Vertebral Compression Fractures in Ankylosing Spondylitis: Data from the National Inpatient Sample 2001-2014
Anish Paudel¹, Rashmi Dhital², Dilli Poudel³, Anthony Donato¹ and Paras Karmacharya⁴, ¹Reading Hospital and Medical Center, West Reading, PA, ²Reading Hospital and Medical Center, West Reading, ³University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Rochester MN, ROCHESTER, MN
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly affecting the spine, leading to syndesmophyte formation, ankylosis, and osteoporosis. These factors have been associated…
Abstract Number: 0156 • ACR Convergence 2020
The Role of Biological Treatment in the Health-Related Quality of Life of Ankylosing Spondylitis Patients’ Assessment – Meta-Analysis
Wojciech Tański¹, Mariusz Chabowski², Natalia Świątoniowska-Lonc³ and Beata Jankowska-Polańska³, ¹4th Military Teaching Hospital, Wrocław, Poland, ²4th Military Teaching Hospital, Wroclaw Medical University, Wrocław, Poland, ³Wroclaw Medical University, Wrocław, Poland
Background/Purpose: Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease involving the axial skeleton, entheses and peripheral joints, and may occur together with extra-articular manifestations, such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].